Price
2,819.3
-0.03%52W Range
Market Cap
₹46,507.08 Cr
Traded: ₹69.05 Cr (0.15%) 0.0x
Free Float: ₹4,213.54 Cr (1.64% of FF traded)
Volume · 60D trend
2.45 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| Sales | -- | +13.0% | +21.0% | -- | +18.0% | Stable |
| ROE | -- | +11.0% | +9.0% | -- | -- | Decelerating |
| Return | -- | -8.0% | +17.0% | +38.0% | -- | Accelerating |
| Profit | -- | +1.0% | +8.0% | -- | +49.0% | Accelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,800 | 1,743 | 1,695 | 1,487 | 1,506 | 1,425 | 1,384 | 1,406 | 1,402 | 1,537 | 1,545 | 1,373 | 1,209 | 785 | 938 |
| Expenses | 1,311 | 1,230 | 1,260 | 1,173 | 1,138 | 1,077 | 1,024 | 1,109 | 1,137 | 1,179 | 1,189 | 1,049 | 915 | 617 | 649 |
| Operating Profit | 489 | 513 | 435 | 314 | 368 | 348 | 360 | 297 | 264 | 359 | 356 | 324 | 294 | 168 | 290 |
| OPM % | 27.0% | 29.0% | 26.0% | 21.0% | 24.0% | 24.0% | 26.0% | 21.0% | 19.0% | 23.0% | 23.0% | 24.0% | 24.0% | 21.0% | 31.0% |
| Other Income | 61 | 111 | 39 | 84 | 58 | 44 | 58 | 60 | 51 | 42 | 37 | 53 | 38 | -18 | 62 |
| Interest | 4 | 10 | 4 | 8 | 12 | 7 | 23 | 6 | 6 | 10 | 5 | 6 | 5 | 2 | 3 |
| Depreciation | 111 | 109 | 108 | 106 | 101 | 96 | 96 | 94 | 92 | 93 | 105 | 81 | 65 | 38 | 38 |
| Profit Before Tax | 435 | 506 | 362 | 284 | 313 | 288 | 299 | 257 | 218 | 298 | 283 | 290 | 261 | 111 | 311 |
| Tax % | 27.0% | 28.0% | 28.0% | 35.0% | 31.0% | 35.0% | 32.0% | 36.0% | 34.0% | 35.0% | 32.0% | 33.0% | 26.0% | 29.0% | 25.0% |
| Net Profit | 317 | 367 | 261 | 184 | 215 | 187 | 205 | 164 | 144 | 192 | 192 | 194 | 194 | 79 | 232 |
| Exceptional Items | -- | 0 | -24 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -56 | 0 |
| EPS (Rs) | 19.2 | 22.3 | 15.9 | 11.2 | 13.1 | 11.3 | 12.4 | 9.9 | 8.7 | 11.7 | 11.7 | 11.8 | 11.8 | 4.8 | 14.1 |
| Sales Growth (YoY) | -- | 22.3% | 22.5% | 5.8% | 7.4% | -7.3% | -10.4% | 2.4% | 16.0% | 95.8% | 64.7% | 31.5% | 41.0% | -28.8% | -- |
| Sales Growth (QoQ) | -- | 2.8% | 14.0% | -1.3% | 5.7% | 3.0% | -1.6% | 0.3% | -8.8% | -0.5% | 12.5% | 13.6% | 54.0% | -16.3% | -- |
| OP Growth (YoY) | 32.9% | 47.4% | 20.8% | 5.7% | 39.4% | -3.1% | 1.1% | -8.3% | -10.2% | 113.7% | 22.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -4.7% | 17.9% | 38.5% | -14.7% | 5.7% | -3.3% | 21.2% | 12.5% | -26.5% | 0.8% | 9.9% | 10.2% | 75.0% | -42.1% | -- |
| Profit Growth (YoY) | -- | 97.0% | 36.0% | 12.0% | 50.0% | -3.0% | 7.0% | -16.0% | -26.0% | 70.0% | -17.0% | -20.0% | -15.0% | -60.0% | -15.0% |
| EPS Growth (YoY) | -- | 96.6% | 27.8% | 12.3% | 49.8% | -3.1% | 6.6% | -15.7% | -25.9% | 144.3% | -17.3% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 40.3% | 42.3% | -14.8% | 15.6% | -8.9% | 25.1% | 13.8% | -25.3% | 0.3% | -1.1% | -0.1% | 146.7% | -66.0% | -- |
| OP Margin | -- | 29.4% | 25.7% | 21.1% | 24.4% | 24.4% | 26.0% | 21.1% | 18.8% | 23.4% | 23.0% | 23.6% | 24.3% | 21.4% | 30.9% |
| Net Margin | -- | 21.1% | 15.4% | 12.4% | 14.3% | 13.1% | 14.8% | 11.7% | 10.3% | 12.5% | 12.4% | 14.1% | 16.1% | 10.1% | 24.7% |
| Material Cost % | -- | 33.9% | 34.0% | 37.3% | 34.6% | 34.2% | 33.4% | 40.9% | 40.3% | 39.0% | 38.8% | 38.0% | 37.5% | 46.5% | 45.5% |
| Employee Cost % | -- | 23.6% | 25.0% | 25.9% | 27.1% | 26.2% | 24.8% | 23.5% | 25.4% | 22.9% | 22.4% | 22.2% | 21.1% | 13.1% | 10.8% |
| P/S | 6.92 | 6.84 | 5.12 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 41.16 | 42.77 | 36.92 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.49 | 4.60 | 3.27 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Schedule of Investor Meet
Q1FY27 Earnings Call Transcript
Appointment of Chief Executive Officer of the Company
Newspaper Publication on Q1FY27 Financial Results
Q1FY27 Earnings Call Audio recording
Schedule of Investor Meets
Investor Presentation on Q1FY27 Financial Results
Press release on Q1FY27 Financial Results
Unaudited Financial results for the quarter ended June 30, 2026
Outcome of Board Meeting
Gland Pharma announces strategic CDMO partnership with a Global Pharmaceutical Company
BRSR Report for the year ended March 31, 2026
Annual Report for the FY 2025-26
Notice of 48th AGM
Q1FY27 Earnings Call Intimation
Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve Unaudited Standalone and Consolidated ....
Postal Ballot Outcome
Scrutinizers Report on the Postal Ballot
Intimation of Order passed by the Customs Authority
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mirae Asset Mutual Fund
Certificate under Reg 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended June 30, 2026
Closure of Trading Window
Schedule of Investor Meet
Copy of Newspaper Publication
Notice of the Postal Ballot
Schedule of Investor Meet
Schedule of Investor Meet Intimation
Please find enclosed the announcement
Outcome of Board Meeting - 15.06.2026
Changes among Board of Directors of the Company
Resignation of Mr. C.S.N. Murthy, Independent Director of the Company with effect from the close of business hours on June 15, 2026
Copy of Newspaper Publication
Allotment of 2,03,259 Equity Shares on exercise of Employee Stock Options
Schedule of Investor Meet
Schedule of Investor Meet
Q4FY26 Earnings Call Transcript
Annual Secretarial Compliance Report for the year ended March 31, 2026
Schedule of Investor Meet
Copy of Newspaper Publication
Q4FY26 Earnings Call Recording
Grant of Stock Options under Gland Pharma Employee Stock Option Scheme 2025
Board fixes Record date of August 11, 2026 for the Final Dividend
The 48th AGM of the Company will be held on August 25, 2026
Board approves final dividend of Rs. 20/- per share, subject to approval of shareholders in the ensuing 48th AGM
Press Release on Q4FY26 Audited Financial Results
Outcome of Board Meeting - 15052026
Investor Presentation on Q4FY26 Financial Results
Q4FY26 Audited Financial Results
Outcome of Postal Ballot
Reappointment of Ms. Naina Lal Kidwai, Independent Director
Annual Reports
6Credit Ratings
4Concalls
24Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Jan 2023
31 Jan 2023Nov 2022
30 Nov 2022Oct 2022
31 Oct 2022Jul 2022
31 Jul 2022May 2022
31 May 2022Jan 2022
31 Jan 2022Nov 2021
30 Nov 2021Sep 2021
30 Sept 2021Jul 2021
31 Jul 2021May 2021
31 May 2021Feb 2021
28 Feb 2021Dec 2020
31 Dec 2020Held by ETFs
21 ETFs hold gland · sorted by weight
Held by Mutual Funds
87 schemes hold gland · sorted by weight